Global investor The Carlyle Group sold a 10.88% stake in Viyash Scientific for ₹1,259.4 crore on August 26. The sale led to a 5.37% drop in the stock price, though institutional buyers like Kotak Mahindra AMC and Bandhan Mutual Fund absorbed a significant portion of the shares.
The Carlyle Group, a global private equity firm, significantly reduced its holding in Viyash Scientific on August 26, 2026. Through its entities CA Hull Investments and CA Harbor Investments, the firm offloaded 4.75 crore shares, representing 10.88% of the company's total equity. The transaction, executed through open market deals, was valued at approximately ₹1,259.4 crore.
Following the announcement, Viyash Scientific shares fell 5.37% on the National Stock Exchange to close at ₹263.4. Large share sales by private equity investors often create short-term selling pressure as the market absorbs the sudden increase in available supply. However, the transaction also saw participation from institutional investors, which is often viewed by market participants as a sign of underlying interest.
Prominent mutual fund houses, including Kotak Mahindra AMC and Bandhan Mutual Fund, stepped in to purchase a portion of the offered shares. Specifically, Kotak Mahindra AMC acquired 24.69 lakh shares, while Bandhan Mutual Fund bought 28.43 lakh shares. Other participants in the block deals included Edelweiss Mutual Fund, Panvira India Innovation Fund, S Gupta Homes, and Aagam Investments.
Inorganic Growth and Execution Risks
For investors, the long-term performance of Viyash Scientific is closely tied to its strategy of aggressive inorganic growth. The company has been expanding its operations through acquisitions, such as the purchase of BioForLife Italia. While such moves can expand market reach and product capabilities, they also bring operational challenges. Integrating new businesses requires careful management to ensure that the expected financial benefits are realized without hurting profit margins or increasing debt levels.
Another point for investors to consider is the reliance on institutional sentiment. As private equity firms like Carlyle move toward exit cycles, further stake sales could occur in the future. While institutional buying can provide a floor for the stock price during these sales, the company's valuation and share performance will ultimately depend on its ability to deliver consistent growth and manage the complexities of its expanded business model.
Investors may monitor the company’s upcoming quarterly financial filings to see how the recent acquisitions are impacting revenue and margins. The stability of the stock price following this large block deal and the ability of the management team to execute on their integration plans will be the key areas to track in the coming months.